← All Wire coverage

Situationmaterial

US FDA approves Replimune's skin cancer drug

Carried more widely than almost anything else in the last 30 days

Reports

15

Domains carrying it

14

First reported

6 August 2026

Latest report

10 August 2026

Sectors

Biotech

Where

United States

Timeline

  1. 6 August 2026US FDA approves Replimune's skin cancer drugkfgo.com
  2. 7 August 2026FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant ...biospace.com
  3. 8 August 2026FDA Grants Accelerated Approval to Tudriqev Plus Nivolumab for Advanced Melanomaoncodaily.com
  4. 9 August 2026FDA Approves Replimune's Tudriqev for Advanced Melanoma After Two Previous Rejectionsmedicaldaily.com
  5. 10 August 2026New Melanoma Drug Based On Herpes Virus Granted FDA Accelerated Approvalusnews.com
  6. 10 August 2026FDA reverses course, approves melanoma therapy after 2 rejectionsbeckersoncology.com

Connected developments

Situations Wire finds semantically close to this one. Proximity, not cause.

Share

Wire has not analysed this situation yet

Below is every report Wire has gathered on this event, and the situations it connects to. The deeper analysis — why it happened, what changed, what would prove it wrong — is not written yet, so nothing here claims it.

Evidence

15 reports · 14 domains